Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) PT at $19.64

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been assigned an average rating of “Moderate Buy” from the thirteen analysts that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $19.6364.

A number of equities research analysts have recently issued reports on BCRX shares. Royal Bank Of Canada cut their target price on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. HC Wainwright lifted their price target on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Weiss Ratings upgraded BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Wednesday, March 4th. Finally, Evercore started coverage on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price objective for the company.

Insider Activity

In related news, insider Alane P. Barnes sold 150,000 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $9.15, for a total value of $1,372,500.00. Following the completion of the sale, the insider owned 400,703 shares in the company, valued at approximately $3,666,432.45. This represents a 27.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.10% of the stock is owned by corporate insiders.

Institutional Trading of BioCryst Pharmaceuticals

Several large investors have recently added to or reduced their stakes in BCRX. Rockefeller Capital Management L.P. boosted its position in shares of BioCryst Pharmaceuticals by 403.2% in the fourth quarter. Rockefeller Capital Management L.P. now owns 26,797 shares of the biotechnology company’s stock worth $209,000 after buying an additional 21,472 shares during the period. Invesco Ltd. raised its position in BioCryst Pharmaceuticals by 40.8% during the fourth quarter. Invesco Ltd. now owns 1,354,897 shares of the biotechnology company’s stock valued at $10,568,000 after buying an additional 392,521 shares during the period. Mackenzie Financial Corp raised its position in BioCryst Pharmaceuticals by 16.6% during the fourth quarter. Mackenzie Financial Corp now owns 150,728 shares of the biotechnology company’s stock valued at $1,152,000 after buying an additional 21,411 shares during the period. NewEdge Advisors LLC purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter worth about $390,000. Finally, XTX Topco Ltd purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter worth about $133,000. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $9.33 on Tuesday. The firm has a market cap of $2.34 billion, a price-to-earnings ratio of 7.78 and a beta of 0.74. BioCryst Pharmaceuticals has a 1 year low of $6.00 and a 1 year high of $11.31. The firm’s 50 day moving average price is $7.77 and its two-hundred day moving average price is $7.48.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Thursday, February 26th. The biotechnology company reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $1.05. The company had revenue of $163.28 million during the quarter, compared to the consensus estimate of $151.32 million. BioCryst Pharmaceuticals had a negative return on equity of 84.33% and a net margin of 30.16%.The company’s quarterly revenue was up 209.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.13) EPS. As a group, equities analysts predict that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.